Dubai Ranks First Globally in FDI for Cultural and Creative Industries 2023
6.6.2024 18:32:00 EEST | Business Wire | Press release
Dubai has topped the Foreign Direct Investment (FDI) Index for cultural and creative industries in 2023, according to the 'fDi Markets' report by the Financial Times. This ranking reaffirms Dubai’s leadership and enhances its competitiveness as a global capital of the creative economy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240606835811/en/
Dubai topped the Foreign Direct Investment Index for cultural and creative industries in 2023 per the Financial Times’ fDi Markets report (Graphic: AETOSWire)
The emirate ranked first globally as the top destination for job creation and capital inflows in the cultural and creative industries (CCI) sector, out of 115 other destinations in the report. This achievement places Dubai ahead of major global cities such as London, New York, and Singapore.
According to data from the Dubai FDI Monitor, released by the Dubai Department of Economy and Tourism (DET), Dubai has attracted 898 projects in the cultural and creative industries sector in 2023, almost double the figure from the previous year. This led to AED 11.8 billion in FDI capital inflow, which was a 60% increase. An estimated 21,563 new job opportunities were created in 2023, 74% up on 2022.
Within the ranking of the top five source countries for FDI capital inflows into CCI in Dubai during 2023, data from the Dubai FDI Monitor and the Dubai Framework for Cultural Statistics showed an increase in capital inflows. The US led with 33.2%, followed by the UK at 12.4%, India with 9.1%, Hungary on 4%, and Denmark’s 3%. The US also topped the list for creating new job opportunities through FDI into Dubai’s CCI with 19.2%, India boasting 16.3%, the UK 15.7%, Singapore with 5%, and France’s 4.2%.
In terms of the number of FDI projects announced in 2023 in the CCI sector, the UK led with 17.8%, followed by India with 16.9%, the US at 16%, France with 4%, and Italy’s 3.8%, highlighting Dubai’s efforts and strategies to focus on these markets as key partners.
Data from the Dubai FDI Monitor and the Dubai Framework for Cultural Statistics indicated that wholly-owned Greenfield FDI projects accounted for 78.7% of Dubai’s total CCI in 2023. New Forms of Investments (NFIs) were 16.1%, reinvestment projects made up 3%, and mergers and acquisitions tallied up to 2.1% of the projects in the registered sectors.
Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240606835811/en/
Contact information
Joumana Alkhani
joumana.ak@cbpr.me
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Visa Unveils New Services to Modernize Dispute Resolution Process1.4.2026 16:00:00 EEST | Press release
Visa (NYSE: V), a global leader in digital payments, today announced six new dispute resolution tools designed to reduce the billions of dollars lost annually to inefficient, outdated dispute processes. The expanded suite of dispute resolution services is being designed to help merchants and financial institutions cut administrative costs, reduce fraud-related losses and redirect those resources toward growth, innovation and customer experience. Disputes remain one of the most persistent friction points in commerce, driving rising costs for merchants and financial institutions while simultaneously leaving consumers frustrated and confused. In 2025, Visa processed 106 million disputes globally, a 35% increase since 20191. "Dispute management is moving from a back-office function to a strategic priority, driven by rising volumes, regulatory scrutiny, and growing pressure to protect customer experience," says Sam Abadir, Research Director, Risk, Compliance & Financial Crime, IDC Financial
Neuphonic and Rapport Bring Real-Time Digital Humans to Everyday Hardware1.4.2026 16:00:00 EEST | Press release
Neuphonic and Rapport (a division of Speech Graphics) today announced a partnership to deliver what they believe is among the first fully real-time, photorealistic digital human systems running entirely on standard CPU hardware. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260401782320/en/ Rapport and Neuphonic announce a partnership to deliver next-generation conversational AI experiences. The collaboration combines Neuphonic’s ultra-low latency text-to-speech technology with Rapport, an interactive AI avatar role play platform powered by production-proven real-time facial and full-body animation technology from Speech Graphics, used in video games such as Call of Duty, The Last of Us Part II and Hogwarts Legacy. Together, the system generates natural voice, perfectly synchronised lip movement and emotionally responsive facial performance in under 100 milliseconds — enabling digital characters that can speak, react and ex
Rimini Street Announces Debt Reduction and Amendment to its Credit Agreement1.4.2026 16:00:00 EEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™, and the leading third-party support provider for Oracle, SAP and VMware software, today announced first quarter debt reduction activities and a recent amendment to its credit agreement. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260401160360/en/ Rimini Street Announces Debt Reduction and Amendment to its Credit Agreement Debt reduction activities during the first quarter of 2026 totaled $10.9 million, reducing the Company’s outstanding term loan to $58.4 million as of March 31, 2026. The Company’s credit agreement was amended effective as of March 27, 2026 to increase to $20.0 million the value of Company common stock that could be repurchased per annum, beginning with the Company’s 2026 fiscal year and for each fiscal year thereafter, with a revised total of $50.0 million in permitted stock repurchases from the period beginning January
Netceed Strengthens Board with Global Infrastructure and Technology Leaders1.4.2026 15:00:00 EEST | Press release
Netceed, a global leader in delivering supply chain solutions across broadband, data center and energy infrastructure, today announced the appointment of Franck Bruel, Jan Frykhammar and Stacey Thompson to advise as strategic advisors to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260401045867/en/ Franck Bruel Following the recently announced recapitalization of the Netceed Group and under the chairmanship of Rajeev Suri, the company is strengthening its Board with globally recognized leaders across telecommunications infrastructure, industrial distribution, energy infrastructure and hyperscale technology. Collectively, the new appointees bring decades of leadership experience across some of the world’s most influential infrastructure and technology companies, reflecting Netceed’s ambition to play a leading role in the next generation of global digital, AI and energy infrastructure. Rajeev Suri, Ch
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK ® and TRIKAFTA ® , Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 14:30:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported by clinical and/or in vitro data from 564 variants demonstrating response to ALYFTREK and 521 variants demonstrating response to TRIKAFTA. As such, approximately 800 more people with a clinical diagnosis of CF in the U.S. are now eligible for a medicine that treats the underlying cause of their disease for the first time. This extension means approxim
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom